Haleos Labs Q2 FY26 results revenue lower profit mixed

Revenue DeclineEbitda Margin CompressionRelated Party TransactionsResults View source PDF Explain this filing

HALEOSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹1210.00

prior close

₹1219.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+3.4% vs market

Pharmaceuticals peers, median of 157sector-0.2%+3.4% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.5

15m

+0.3

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1-0.3+3.4-0.2+3.4

Next day

+4.8+0.7+4.1+0.5+4.3

+5.4+0.6+4.8+0.6+4.8

+8.4+0.5+8.0+0.3+8.1

+9.9+1.1+8.8+0.2+9.7

+11.2+0.3+11.0-0.6+11.9

+11.6-0.2+11.8-1.1+12.7

15d

+13.2-2.2+15.5-2.1+15.3

+12.4-4.9+17.3-3.2+15.6

+7.4-7.5+14.8-5.9+13.3

+8.9-4.8+13.7-6.4+15.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Company (formerly SMS Lifesciences India, renamed in Aug 2025) reported Q2 and H1 FY26 standalone results. H1 standalone revenue fell to Rs 15,689 lakh from Rs 16,507 lakh YoY, a drop of 5 percent. Standalone net profit declined 19 percent to Rs 1,014 lakh from Rs 1,247 lakh. Consolidated H1 revenue was Rs 16,387 lakh vs Rs 17,101 lakh, while consolidated PAT rose slightly to Rs 1,081 lakh from Rs 1,040 lakh. Auditor Rambabu and Co gave an unmodified limited review opinion. Related party transactions were disclosed.

Likely market impact

Weak standalone performance with falling revenue and profit may pressure the stock, partly offset by a small rise in consolidated PAT.